[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507581":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":26,"responsibleParty":100,"collaborators":18,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":106,"sex":112,"minAge":18,"maxAge":18,"enrollmentInfo":113,"targetDuration":18,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":29,"whyStopped":18,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Zealand University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ctDNA monitoring","EXPERIMENTAL","Treatment monitoring by longitudinal circulating tumor DNA measurements and Quality of Life assessments",[13],"Other: Circulating tumor DNA treatment monitoring",{"label":15,"type":16,"description":17,"interventionNames":18},"CT scan monitoring","NO_INTERVENTION","Treatment monitoring by longitudinal CT scans (standard) and Quality of Life Assessments",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Circulating tumor DNA treatment monitoring","A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)",[9],[25],"Quality of Life assessments",[27,49,66,76,88],{"facility":28,"status":29,"city":30,"state":31,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Department of Clinical Oncology","RECRUITING","Hillerød","Region H","Denmark","DK",{"type":35,"coordinates":36},"Point",[37,38],12.30081,55.92791,{"lat":38,"lon":37},[41,46],{"name":42,"role":43,"phone":44,"phoneExt":18,"email":45},"Stine Wahlstrøm, Medical Oncologist","CONTACT","+45 48296103","stine.wahlstroem.03@regionh.dk",{"name":47,"role":43,"phone":18,"phoneExt":18,"email":48},"Malene S Frank, Medical Oncologist","malf@regionsjaelland.dk",{"facility":50,"status":29,"city":51,"state":52,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Department of Clinical Oncology and Palliative Care","Næstved","Region Sjælland",{"type":35,"coordinates":54},[55,56],11.76092,55.22992,{"lat":56,"lon":55},[59,63],{"name":60,"role":43,"phone":61,"phoneExt":62,"email":48},"Malene Støchkel Frank, MD, PhD","56513279","45",{"name":64,"role":43,"phone":18,"phoneExt":18,"email":65},"Michael Elmkvist Andersen, MD","mielan@regionsjaelland.dk",{"facility":50,"status":29,"city":67,"state":52,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Roskilde",{"type":35,"coordinates":69},[70,71],12.08035,55.64152,{"lat":71,"lon":70},[74,75],{"name":60,"role":43,"phone":61,"phoneExt":62,"email":48},{"name":64,"role":43,"phone":18,"phoneExt":18,"email":65},{"facility":77,"status":78,"city":79,"state":18,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Department of Oncology","NOT_YET_RECRUITING","Aalborg",{"type":35,"coordinates":81},[82,83],9.9187,57.048,{"lat":83,"lon":82},[86],{"name":87,"role":43,"phone":18,"phoneExt":18,"email":18},"Weronika Maria Szejniuk, MD, PhD",{"facility":77,"status":78,"city":89,"state":18,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Vejle",{"type":35,"coordinates":91},[92,93],9.5357,55.70927,{"lat":93,"lon":92},[96,98],{"name":97,"role":43,"phone":18,"phoneExt":18,"email":18},"Christa Haugaard Nyhus, MD",{"name":99,"role":43,"phone":18,"phoneExt":18,"email":18},"Torben Frøstrup Hansen, Professor",{"type":101,"investigatorFullName":102,"investigatorTitle":103,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Malene Støchel Frank","Medical Oncologist, PhD","100507581","circulating-tumor-dna-guided-treatment-monitoring-in-advanced-lung-cancer-100507581",false,"NCT05889247","Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer","Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer - a Randomized Interventional Study","PRELUCA","Inclusion Criteria:\n\n* Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)\n* Advanced or locally advanced disease without curative intended treatment options\n* Age \\> 18 years\n* Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1\n* Measurable disease according to the iRECIST criteria version 1.1.\n* Eligible to first line immunotherapy (monotherapy)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Targetable alterations in EGFR, ALK or ROS-1\n* Other active cancers","ALL",{"count":114,"type":115},350,"ESTIMATED","INTERVENTIONAL",[118],"NA","The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.",[121],"Non-small Cell Lung Cancer Metastatic",[123,124],"liquid biopsy","treatment monitoring","2026-01-06",{"date":127,"type":128},"2026-01-09","ACTUAL",{"date":130,"type":128},"2023-07-28",{"date":132,"type":115},"2032-06",{"name":5,"class":6},5]